09:53 AM EST, 02/25/2025 (MT Newswires) -- Natera ( NTRA ) said Tuesday that its Signatera test for patients diagnosed with lung cancer has met coverage requirements for the Centers for Medicare & Medicaid Services' Molecular Diagnostics Services Program.

The company said the coverage is intended for patients with non-small cell lung cancer, specifically patients with stage 1 through stage 3 NSCLC with resectable or unresectable disease.

Natera ( NTRA ) said the new coverage expands its preexisting Medicare coverage of Signatera for monitoring immunotherapy in adjuvant and metastatic settings.

Price: 154.55, Change: -3.83, Percent Change: -2.42